Archives

img-01

Japan’s New GVP Updates

Japan’s new Pharmaceutical Affairs Law (PAL), effective as of April 1, 2005, outlines the new post-marketing safety measures, also known as Good Vigilance Practice (GVP). This regulation clarifies the responsibilities of distributors of medical devices, drugs, quasi-drugs, and cosmetic products. All Marketing... Read More

img-01

China: Update on Drug Counterfeiting

Although China is making efforts to improve piracy and counterfeit drug enforcement mechanisms, pharmaceutical companies must still be extremely careful in the Chinese market. In fact, currently several large US pharmaceutical companies are facing significant challenges dealing with counterfeit drugs in China.... Read More

img-01

Hong Kong: New Listing System for Medical Devices

In 2003, Hong Kong’s Department of Health (DOH) launched the Medical Device Administrative Control System (MDACS). The first phase of the MDACS, which began on November 26, 2004, permitted medical device companies to voluntarily list their Class IV (high-risk) medical devices. The... Read More

img-01

Medical Distribution in China Opening Up

For the most part, up until recently, only foreign medical companies that manufactured medical products in China could set up their own sales office and distribution scheme in China. However, after joining the WTO in December 2001, China agreed to open up... Read More

img-01

Korea Update: Medical Device Harmonization Efforts

The Korea Food and Drug Administration (KFDA) has continued its efforts on harmonization of medical device standards with the enactment of medical device Good Clinical Practice (GCP) regulations on July 14, 2005. Previously, GCP regulations were not established for medical devices in... Read More